Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer Agensys caverta.

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced they have initiated a Stage I medical trial of AGS-16M8F an antibody-drug conjugate that is being developed for the treating metastatic renal cancers caverta . An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, leading to selective tumor cell eliminating. Despite the availability of many therapies for the treating metastatic renal cancer, there is a significant dependence on new renal cancer therapies, said Leonard Reyno, M.D., Senior Vice President and Chief Medical Officer at Agensys.